Amount Raised
$200 Million
Round Type
Post-IPO Equity
San DiegoBiotechnologyTherapeuticsBiopharmaInvestors
Description
Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that it has entered into a securities purchase agreement for a private placement financing (the "PIPE") that is expected to result in gross proceeds of approximately $200 million. The financing was limited to certain of the Company's existing investors, which included participation from RA Capital Management as the lead investor, Viking Global Investors, Perceptive Advisors, and TCGX.
Quick answer
Inhibrx raised $200 Million in a Post-IPO Equity round, dated August 29, 2023. Investors: Tcgx, Perceptive Advisors, Viking Global Investors and RA Capital Management. Inhibrx is based in San Diego, California, United States.
- How much did Inhibrx raise?
- Inhibrx raised $200 Million in a Post-IPO Equity round on August 29, 2023.
- Who invested in Inhibrx?
- Tcgx, Perceptive Advisors, Viking Global Investors and RA Capital Management are named as investors in this round.
- What does Inhibrx do?
- Inhibrx is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases.
- Where is Inhibrx based and how big is it?
- Inhibrx is based in San Diego, California, United States. Fundz records about 110 employees.
- Who are the decision-makers at Inhibrx?
- Fundz holds 1 contact at Inhibrx, including the Executive Officer, Director. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biopharma around the same time
Companies in the same sectors as Inhibrx that raised within 45 days of this round, from Fundz verified event records.
- Acasti raised $7.5M (Post-IPO Equity) on September 26, 2023.
- Acasti raised $7.5M on September 25, 2023.
- Entero Therapeutics raised $1.5M (Seed) on September 14, 2023.
- DalCor Pharmaceuticals raised $80M (Series D) on September 13, 2023.
- Renibus Therapeutics raised an undisclosed amount (Series B) on September 12, 2023.
- Gracell raised $150M (Post-IPO Equity) on August 7, 2023.
Who to call at Inhibrx, and when
A new round usually means Inhibrx is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Inhibrx raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Inhibrx, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Inhibrx. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Inhibrx raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Inhibrx raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.